In this report we present a unique case of YST differentiation arising from a recurrent urothelial carcinoma in a 76-year-old man. This tumor showed a mixture of several histologic patterns, including a sarcomatoid component, which is extremely infrequent.
According to the evidence available, YSTs may arise from benign and malignant somatic lesions in several organs. For example, it is well documented the transformation of benign or malignant ovarian and endometrial tumors into YST [6]. Neoplasms with YST differentiation have also been observed in the sinonasal region, where they have been denominated teratocarcinosarcoma [7], in the stomach, colon, and lung [8]. YST differentiation is not recognized as a histological variant in the current WHO classifications of urothelial carcinoma. However, some reports of urinary neoplasms showing some YST-like features are available in the literature. The majority of these cases have been summarized in a previous publication by Samaratunga et al. [4], which included one urothelial carcinoma, and four adenocarcinomas of the renal pelvis, all exhibiting hepatoid areas and AFP positivityeight cases of bladder adenocarcinoma with hepatoid areas, and two cases of conventional bladder urothelial carcinoma, all of them showing AFP positivity. Reports of urothelial carcinoma with SALL4 positive areas are also available [9]. Among those cases, additional immunochemistry studies have not been performed to confirm YST differentiation. McNamee et al. proposed the term “somatically derived YSTs” [2] to denominate the spectrum of somatic neoplasms with YST-like features arising most frequently in somatic neoplasms, and suggested unification of the terminology between different sites where such neoplasms occur.
Histologically, our case showed a mixture of diverse patterns, ranging from classical reticular-microcystic to sarcomatoid pattern with chondroid differentiation. Indeed, the most relevant histological characteristic of the somatic neoplasms with YST differentiation is the identification of several patterns, which can be grouped in two categories: the classical ones, which comprise reticular-microcystic, polyvesicular, vitelline, solid and parietal patterns, and the special ones, which comprise glandular, hepatoid and sarcomatoid patterns [1]. The glandular pattern, also referred to as “enteroblastic”, is the most frequently observed among somatic neoplasms with YST differentiation [2], while sarcomatoid pattern is extremely uncommon [10]. In addition to the morphologic features, the diagnosis of YST differentiation requires confirmation with a characteristic immunohistochemistry profile. A majority of these neoplasms shows positivity for AFP, SALL4, and negativity for differentiated epithelial markers, such as CK7 and EMA [2]. CDX2 is usually positive in areas with glandular pattern, while hepatic differentiation markers, such as HepPar 1, may be positive in hepatoid areas. Our case showed the described immunohistochemistry profile, in agreement with the diagnosis of YST differentiation. Moreover, immunohistochemistry performed in previous biopsy specimens, showed similar results in the areas with glandular differentiation (Figure 1).
We identified genetic alterations in the short arm of chromosome 12, which showed a polysomic pattern, but an i12p was not identified. The polysomic pattern of 12p abnormality has been described previously in germ cell tumors of the central nervous system, although it is of unknown significance [5]. Chromosome 12 abnormalities, either as an i12p or as 12p overrepresentation, are the hallmark cytogenetic alteration of germ cell tumors. These alterations are identified in the majority of gonadal germ cell tumors, with few exceptions [11], and in somatic type malignancies, derived from germ cell tumors. However, the occurrence of chromosome 12 abnormalities is not well established in somatic neoplasms with YST differentiation. While some authors identified i12p and other alterations of chromosome 12 [12], other authors reported cases without i12p, arguing that their results were consistent with the possible somatic origin of the YST component in these neoplasms [10]. The contradictory results may be due to problems in interpretation of the FISH, which is a common assay to identify i12p, but can be difficult to evaluate, and lacks of ideal sensitivity and specificity [13]. Also, the results may be explained by uncertainties regarding the actual origin of the neoplastic cells in somatic tumors with YST differentiation, which may derive from somatic neoplastic cells through a process of retrodifferentiation or neometaplasia, or from a pluripotential embryonic stem/germ cell [2]. Currently, further investigation is required to better characterize genetic alterations in YSTs derived from somatic neoplasms, and to elucidate their actual histogenesis.
Our patient had some clinical characteristics described previously among patients with urinary tumors exhibiting YST features. According to the available reports [4], these tumors are more frequently diagnosed among men of 73 years-old on average, thus differing from primary extragonadal YST that are more common in young patients. Elevated serum Alphafetoprotein (AFP) levels may be also observed among these patients. Regarding our case, these levels were not determined, because this enzyme is not routinely measured in post-surgical controls of adult patients with a bladder carcinoma. However, AFP serum levels should be determined in patients with urothelial neoplasms exhibiting infrequent histological patterns (e.g. glandular or hepatoid), because the elevation of these levels support the diagnosis of YST differentiation. Moreover, these determinations may be used to control the postsurgical evolution, and to detect tumor relapse among these patients [14].
Differential diagnosis included metastatic YST from the testicles, primary extragonadal YST, sarcomatoid urothelial carcinoma, chordoid urothelial carcinoma [15], and carcinoma with enteroblastic or hepatoid differentiation. Metastatic YST and primary extragonadal YST of the bladder are extremely infrequent, and were ruled out after the revision of previous biopsies from the same anatomical location, which showed a primary tumor comprised of conventional urothelial carcinoma admixed with areas of glandular differentiation (Figure 1). These latter areas were morphologically and histochemically similar to the glandular component of the cystectomy specimen, supporting the diagnosis of urothelial carcinoma with YST differentiation. Sarcomatoid and chordoid urothelial carcinoma were excluded after the identification of areas with classical YST pattern and immunohistochemistry results. Carcinoma with enteroblastic differentiation has been reported in several organs (gastrointestinal, lung, etc) [16], while carcinoma with hepatoid differentiation has been mainly reported in gynecologic tumors [17], and in urinary tract tumors already mentioned [4]. These neoplasms show some histologic and immunohistochemical features, similar to those identified in our case. As previously discussed, according to some authors [2], tumors with enteroblastic and/or hepatoid differentiation could be considered part of the wide spectrum of the so-called SD-YSTs.
In summary, this is a unique case of a bladder urothelial carcinoma with YST differentiation, showing multiple and complex histological patterns. YST differentiation should be suspected in adult patients with extragonadal somatic tumors, also urothelial carcinoma, exhibiting diverse histological patterns, particularly glandular and hepatoid. The diagnosis of YST differentiation in somatic neoplasms requires confirmation with immunohistochemistry results, which necessarily include positivity for AFP, GLP3 and SALL4, and negativity for epithelial markers like CK7 and EMA. Elevated AFP serum levels may support the diagnosis, when this determination is available.